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Abstract
Background: Data on clinical outcomes among patients treated with the zotarolimus-eluting Endeavor™ stent
versus the sirolimus-eluting Cypher™ stent favor the sirolimus-eluting stent. However, a separate comparison of
clinical outcome among patients treated for multiple lesions with these stents is lacking. We performed this
comparison within the SORT OUT III trial data set.
Methods: Among 2332 patients randomized in SORT OUT III, 695 were treated for multiple lesions with
zotarolimus-eluting (n = 350) or sirolimus-eluting (n = 345) stents and followed for 18 months. Major adverse
cardiac events (MACE); composite of cardiac death, myocardial infarction, or target vessel revascularization (TVR);
was the primary endpoint.
Results: Zotarolimus-eluting compared to sirolimus-eluting stent treatment was associated with increased MACE
rate (13.2% vs. 2.6%; hazard ratio 5.29 with 95% confidence interval: 2.59-10.8). All secondary endpoints; all cause
death, cardiac death, myocardial infarction, TVR, target lesion revascularization, in-stent restenosis, and definite stent
thrombosis; were observed more frequently among zotarolimus-eluting stent treated patients. For all endpoints,
hazard ratios were 1.6 to 4.6 times higher than in the overall results of the SORT OUT III trial.
Conclusions: We observed better clinical outcomes among patients treated for multiple lesions with the sirolimus-
eluting stent compared to those treated with the zotarolimus-eluting stent.
Background
Percutaneous coronary intervention (PCI) with drug
eluting stent (DES) implantation in single coronary
artery lesions has become mainstay [1]. Gradually, PCI
with DES of multiple coronary artery lesions, concomi-
tantly, has increased, and PCI of multiple lesions in
patients with multivessel disease is under evaluation as
an alternative or supplement to coronary artery bypass
surgery [2].
In some stent trials with comparison of zotarolimus-
eluting and sirolimus-eluting stents, however, stent
safety and efficacy have only been evaluated in patients
with single lesions [3]. In other trials and registry
studies, patients with single and multiple lesions have
been analyzed together [4-6]. Trials comparing the
zotarolimus-eluting Endeavor™ stent and the sirolimus-
eluting Cypher™ stent generally favor the sirolimus-
eluting stent [7]. However, a separate analysis of data on
patients treated for multiple lesions has not been
reported. Considering the current use of DES to treat
multiple lesions concomitantly, such a separate analysis
is relevant. In the SORT OUT III trial, we compared
clinical outcome among all-comers randomized to the
zotarolimus-eluting Endeavor™ stent and the sirolimus-
eluting Cypher™ stent [5]. In this trial, patients with
multiple lesions were included. Here, we make a sepa-
rate comparison of clinical outcomes among patients
treated for multiple lesions with zotarolimus-eluting and
sirolimus-eluting stents in the SORT OUT III trial.
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This study was approved by the local ethics committee
and complied with the Declaration of Helsinki. Patients
provided written, informed consent before participation.
The SORT OUT III trial was registered with Clinical-
Trials.gov (NCT00660478).
In the framework of the SORT OUT organization, we
undertook the SORT OUT III trial; a multi-centre,
open-label, randomized, all-comer trial from January
2006 through August 2007 in five Danish high-volume
PCI centers [5]. We included patients 18 years or older
undergoing PCI. Patients were eligible when they
needed DES stent treatment of at least one coronary
lesion. There were no upper limits on the number of
treated lesions, treated vessels, or lesion length. When
more than one lesion required treatment, the allocated
study stent should be used to treat all lesions. Exclusion
criteria were: inability to provide informed consent; life
expectancy of less than one year; allergy to acetylsalicylic
acid, clopidogrel, ticlopidine, sirolimus, or zotarolimus;
or participation in another randomised trial. Concurrent
diseases or advanced age did not preclude participation.
In this substudy, we analyzed clinical outcomes among
patients undergoing PCI for multiple lesions (more than
one) at the index PCI. When PCI of more than one
lesion was needed, non-allocated DES or bare metal
stents were only implanted if the allocated study stent
could not be implanted.
At the time of the index PCI, we recorded cardiovas-
cular risk factors and comorbidity and calculated Charl-
son comorbidity score [8,9].
Using a telephone allocation service, we randomized
patients after diagnostic coronary angiography and
before PCI. With block randomization according to cen-
ter, patients were randomized 1:1 to receive either the
zotarolimus-eluting (Endeavor, Medtronic, Santa Rosa,
CA) or the sirolimus-eluting (Cypher Select or Cypher
Select+; Cordis, Johnson & Johnson, Warren, NJ) stent.
Patients were stratified by gender and the presence or
absence of diabetes. Patients were pre-treated with at
least 75 mg acetylsalicylic acid, a 300-600 mg loading
dose of clopidogrel, and 5,000 IU or 70-100 IU/kg
unfractionated heparin. After PCI, dual antiplatelet regi-
mens with lifelong acetylsalicylic acid, 75 mg daily, and
clopidogrel, 75 mg daily, for one year, was recom-
mended in accordance with Danish guidelines [10].
Clinical outcomes were assessed at 18 months. The
primary endpoint was major adverse cardiac events
(MACE) defined as a composite endpoint of cardiac
death, myocardial infarction, and target vessel revascu-
larization (TVR). Other endpoints were all-cause death,
cardiac death, myocardial infarction, TVR, target lesion
revascularization (TLR) (within the stent + 5 mm in
proximal and distal directions), symptom-driven
observation of in-stent restenosis (within the stent + 5
mm in proximal and distal directions), and definite stent
thrombosis. These endpoints have been described pre-
viously [5].
Data on mortalilty (cardiac and non-cardiac), hospital
admissions, coronary angiography, repeat PCI, and cor-
onary bypass surgery were obtained from national Dan-
ish registries (Danish Civil Registration System, National
Registry of Causes of Death, Danish National Registry of
Patients, the local heart registries in the five PCI centers,
and the Danish Heart Register) [11-17]. These cover the
entire Danish population.
Independent study monitors, blinded to treatment
assignment, reviewed all repeat coronary examinations
and interventions (coronary angiography, coronary bal-
loon angioplasty, coronary stent implantation, and cor-
onary artery bypass surgery) and classified their cause as
in-stent restenosis or stent thrombosis based on review
of angiograms and patient files. An independent end-
point committee, also blinded to treatment assignment,
reviewed all events and classified all myocardial infarc-
tions and deaths.
Continuous variables with a normal distribution were
analyzed using the two-sample t-test (Cochran t-test if
the variances were unequal) and continuous variables
with a non-normal distribution using the Mann-Whit-
ney U test. Categorical variables were analyzed using the
Chi-square test. Endpoints were counted in the follow-
up period starting on the date of the index PCI. For
each endpoint, follow up continued until occurrence of
the endpoint event, death, emigration, or until 18
months after stent implantation. We estimated relative
risks using Cox proportional hazards regression analysis.
In the analyses, patients receiving the sirolimus-eluting
stent served as reference group. Analyses were per-
formed according to the intention-to-treat principles.
We used SAS software version 9.2 (SAS Institute Inc.,
Cary, NC, USA) and p < 0.05 was considered statistically
significant.
Results
Among the 2,332 patients randomized to zotarolimus-
eluting or sirolimus-eluting stents in the SORT OUT III
trial, 695 received PCI for multiple (> 1) lesions at the
index PCI. Of these, 350 were allocated to zotarolimus-
eluting stents and 345 were allocated to sirolimus-elut-
ing stents. Baseline patient characteristics were well-
balanced between the zotarolimus-eluting and sirolimus-
eluting stent groups with the exception of previous PCI
which was more common among those receiving zotaro-
limus-eluting stents (Table 1). In total, 810 lesions were
treated in the zotarolimus-eluting stent group and 787
lesions were treated in the sirolimus-eluting stent group
with similar lesion and procedure data, except for a
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treated lesions per patient (Table 2).
The assigned study stent could not be implanted in 1
lesion in a patient allocated to the zotarolimus-eluting
stent and in 11 lesions in patients allocated to the siroli-
mus-eluting stent. This was a statistically significant dif-
ference in stent deliverability (Table 2).
All endpoints occurred more frequently in patients
treated with zotarolimus-eluting stents (Table 3, Figure
1). For MACE, all cause death, myocardial infarction,
TVR, TLR, and in-stent restenosis, the differences were
statistically significant. For cardiac death and definite
stent thrombosis, the differences were not statistically
significant but the hazard ratios were high and in favor of
the sirolimus-eluting stent (6.97 and 4.01, respectively).
Discussion
In the present SORT OUT III sub-study, we observed
better clinical outcomes among patients treated for mul-
tiple lesions with the sirolimus-eluting stent compared
to those treated with the zotarolimus-eluting stent. The
difference was consistent across all endpoints. Thereby,
this study extends findings from previous studies to
patients in need of intervention for multiple lesions [7].
Comparing the difference in clinical outcomes in the
current analysis with the overall SORT OUT III study
results [5], higher hazard ratios were observed for all end-
points. The hazard ratio for MACE was more than two
times higher than in the overall results. The hazard ratios
for all other endpoints were 1.6 (in-stent restenosis) to 4.6
(cardiac death) times higher than in the overall results. In
accordance with the overall results, the outcome differ-
ences were statistically significant for MACE, all cause
death, myocardial infarction, TVR, TLR, and in-stent rest-
enosis while the differences were not statistically signifi-
cant for cardiac death and definite stent thrombosis.
The observed larger difference in outcome in patients
treated for multiple lesions compared to the overall
results supports the relatively consistent findings in favor
of the sirolimus-eluting stent [18]. Our findings are also
in agreement with a subgroup analysis of the SPIRIT III
trial. In SPIRIT III, the outcome among patients treated
with the everolimus-eluting stent (XIENCE V) and the
paclitaxel-eluting stent (TAXUS) were compared favor-
ing the everolimus eluting stent [19]. In a subgroup ana-
lysis of patients treated for 2-vessel disease in SPIRIT III,
patients treated for 2-vessel disease had a larger outcome
difference in favor of the everolimus-eluting stent com-
pared to those treated for 1-vessel disease [20].
W i t hat r u eo u t c o m ed i f f e r e n c ei np a t i e n t sw i t hs i n g l e
lesions, a similar or even more favorable outcome differ-
ence in patients with multiple lesions in general then
seems likely. However, there may be effects that could
not have been predicted from studies on patients with
single lesions and therefore subgroup analyses or specifi-
cally designed studies should be performed in patients
Table 1 Baseline clinical characteristics
Zotarolimus-eluting
stent (n = 350)
Sirolimus-eluting
stent (n = 345)
p
Age (years) 64.8 (10.3) 64.5 (10.4) 0.71
Men 271 (77.4%) 269 (78.0%) 0.86
Family history of coronary artery disease 154 (44.9%) 141 (41.6%) 0.38
Current smokers 94 (28.1%) 100 (30.9%) 0.44
Diabetes mellitus 44 (12.6%) 52 (15.1%) 0.34
Body mass index (kg/m
2) 27.5 (5.6) 27.2 (4.6) 0.44
Hypertension 203 (59.0%) 178 (52.7%) 0.10
Hypercholesterolemia 243 (70.4%) 233 (68.7%) 0.63
Previous myocardial infarction 130 (37.7%) 129 (38.4%) 0.84
Previous percutaneous coronary intervention 72 (20.9%) 48 (14.2%) 0.02
Previous coronary artery bypass surgery 16 (4.6%) 18 (5.3%) 0.68
Charlson comorbidity score 0.35
0 232 (66.3%) 211 (61.2%)
1o r2 98 (28.0%) 109 (31.6%)
3 or more 20 (5.7%) 25 (7.2%)
Indication for intervention 0.19
Stable angina pectoris 195 (55.7%) 177 (51.3%)
ST-segment elevation myocardial infarction 13 (3.7%) 16 (4.6%)
Unstable angina pectoris or non-ST-segment elevation myocardial infarction 129 (36.9%) 146 (42.3%)
Other 13 (3.7%) 6 (1.7%)
Categorical variables are presented as counts (frequency in percent) and continuous variables as means (standard deviation)
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with a type 1 error, and confirmation of a trial result in
similar or associated settings is always settling.
The different event rates observed could be caused by
differences in drugs, drug release kinetics, polymers, or
other factors related to stent design. Any of these para-
meters could affect plaque or vessel wall healing and
thus have impact on the results. This study, however,
was not designed to assess these mechanisms. Likewise,
differences in stent deliverability may be attributed to
many factors in stent design.
There are some limitations to our study. The SORT
OUT III parent study was powered to assess the
composite clinical endpoint, MACE, at 9-month follow-
up [5]. Therefore, this sub-study relying on the SORT
OUT III data after 18 months of follow-up was not
necessarily powered to assess the examined endpoints.
As well, the results obtained in this study for the rapid-
release Endeavor™ stent cannot be extrapolated to
other zotarolimus-eluting stents such as the slow-release
Resolute™ stent [21]. The SORT OUT III trial [5], like
the SORT OUT II trial [22], relied on registry-based
event detection without study-related angiographic or
clinical follow-up. Patient follow-up care was in accor-
dance with normal clinical practice, i.e., a standard clini-
cal outpatient visit at the referring hospital after 1-3
Table 2 Lesion and procedure data
Zotarolimus-eluting stent n = 810 Sirolimus-eluting stent n = 787 p
Number of treated lesions per patient 0.04
2 230 (65.7%) 254 (73.6%)
3 91 (26.0%) 63 (18.3%)
> 3 29 (8.3%) 28 (8.1%)
Number of treated vessels per patient 0.21
1 115 (32.9%) 107 (31.0%)
2 188 (53.7%) 207 (60.0%)
3 47 (13.4%) 31(9.0%)
Target lesion coronary artery 0.45
Left main 17 (2.1%) 13 (1.7%)
Left anterior descending 308 (38.0%) 267 (33.9%)
Left circumflex 222 (27.4%) 229 (29.1%)
Right 261 (32.2%) 276 (35.1%)
Bypass graft 2 (0.2%) 2 (0.3%)
Lesion type 0.09
A 156 (19.3%) 136 (17.5)
B 336 (41.6%) 365 (47.1)
C 316 (39.1%) 274 (35.4)
Length of stented segment per lesion (mm) 19.5 (11.4) 19.7 (12.2) 0.77
Length of stented segment per patient (mm) 45.2 (20.8) 44.9 (20.9) 0.87
Maximal stent diameter (mm) 3.2 (0.5) 3.2 (0.5) 0.84
Use of glycoprotein IIb/IIIa inhibitors 75 (21.4%) 87 (25.2%) 0.24
Assigned study stent could not be implanted 1 (0.1%) 11 (1.4%) 0.003
Categorical variables are presented as counts (frequency in percent) and continuous variables as means (standard deviation)
Table 3 Clinical endpoints
Zotarolimus-eluting
stent (n = 350)
Sirolimus-eluting
stent (n = 345)
Hazard ratio
(95% confidence interval)
Major Adverse Cardiac Events 46 (13.2%) 9 (2.6%) 5.29 (2.59-10.8)
All cause death 16 (4.6%) 5 (1.5%) 3.20 (1.17-8.72)
Cardiac death 7 (2.0%) 1 (0.3%) 6.97 (0.86-56.6)
Myocardial infarction 12 (3.4%) 1 (0.3%) 12.1 (1.57-92.8)
Target vessel revascularization 37 (10.6%) 8 (2.3%) 4.79 (2.23-10.3)
Target lesion revascularization 32 (9.2%) 4 (1.2%) 8.31 (2.94-23.5)
In-stent restenosis 24 (6.9%) 3 (0.9%) 8.23 (2.48-27.3)
Definite stent thrombosis 8 (2.3%) 2 (0.6%) 4.01 (0.85-18.9)
Categorical variables are presented as counts (frequency in percent). Major adverse cardiac events; composite of cardiac death, myocardial infarction, and target
vessel revascularization
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event presentation in routine clinical practice where
patients need to contact the heath care system. This
methodology thus differs from event detection based on
study-driven telephone calls or visits at outpatient
clinics.
Conclusions
We observed better clinical outcomes among patients
treated for multiple lesions with the sirolimus-eluting
stent compared to those treated with the zotarolimus-
eluting stent.
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